Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
NCT ID: NCT04148053
Last Updated: 2019-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2018-11-01
2020-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifcation of Biomarkers for Active Pulmonary Tuberculosis
NCT04490746
Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
NCT04434976
Expression of Tuberculosis in the Lung
NCT00201253
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
NCT06439810
Tuberculosis in China
NCT01071603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active TB
Subjects met the following:
1. Either Pulmonary or Extra-pulmonary tuberculosis patients
2. TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen.
TB-antigen responsive T cell markers
A blood test including a series of T cell markers which are responsive to TB antigens
Latent TB
Subjects met the following:
1. TB Contact in history.
2. Chest X-ray suggestive of non-TB.
3. without any symptoms suggestive of TB.
4. TST and/or IGRA positive.
TB-antigen responsive T cell markers
A blood test including a series of T cell markers which are responsive to TB antigens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TB-antigen responsive T cell markers
A blood test including a series of T cell markers which are responsive to TB antigens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* TB culture and Xpert test required
* Chest X-ray required
Exclusion Criteria
7 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caicun Zhou
Director, Department of Thoracic Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTB18001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.